InMode Ltd. (NASDAQ:INMD) Shares Sold by Captrust Financial Advisors

Captrust Financial Advisors decreased its holdings in InMode Ltd. (NASDAQ:INMD) by 9.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,774 shares of the healthcare company’s stock after selling 1,180 shares during the quarter. Captrust Financial Advisors’ holdings in InMode were worth $200,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of INMD. Asset Dedication LLC acquired a new stake in InMode during the second quarter valued at approximately $33,000. nVerses Capital LLC acquired a new stake in shares of InMode during the 2nd quarter worth approximately $42,000. Nisa Investment Advisors LLC raised its position in shares of InMode by 314.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,550 shares of the healthcare company’s stock worth $60,000 after purchasing an additional 2,694 shares during the period. National Bank of Canada FI grew its holdings in InMode by 40.7% in the 2nd quarter. National Bank of Canada FI now owns 9,406 shares of the healthcare company’s stock worth $168,000 after buying an additional 2,720 shares in the last quarter. Finally, GW Henssler & Associates Ltd. bought a new position in InMode in the 3rd quarter worth approximately $177,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Stock Performance

Shares of NASDAQ INMD opened at $17.97 on Tuesday. The stock has a fifty day moving average price of $18.14 and a two-hundred day moving average price of $17.48. The firm has a market cap of $1.51 billion, a P/E ratio of 9.71 and a beta of 2.07. InMode Ltd. has a 1 year low of $14.87 and a 1 year high of $26.80.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on INMD. Barclays decreased their price objective on InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a report on Monday, October 14th. Needham & Company LLC reissued a “hold” rating on shares of InMode in a report on Thursday, October 31st. Finally, BTIG Research began coverage on InMode in a report on Thursday, October 17th. They issued a “buy” rating and a $25.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $22.60.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.